nach oben

Cardiovascular Toxicology

Erschienen in:

01.06.2007

Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

verfasst von: Brian B. Hasinoff, Eugene H. Herman

Erschienen in: Cardiovascular Toxicology | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Dexrazoxane is highly effective in reducing anthracycline-induced cardiotoxicity and extravasation injury and is used clinically for these indications. Dexrazoxane has two biological activities: it is a prodrug that is hydrolyzed to an iron chelating EDTA-type structure and it is also a strong inhibitor of topoisomerase II. Doxorubicin is able to be reductively activated to produce damaging reactive oxygen species. Iron-dependent cellular damage is thought to be responsible for its cardiotoxicity. The available experimental evidence supports the conclusion that dexrazoxane reduces doxorubicin cardiotoxicity by binding free iron and preventing site-specific oxidative stress on cardiac tissue. However, it cannot be ruled out that dexrazoxane may also be protective through its ability to inhibit topoisomerase II.

Swain, S. M., & Vici, P. (2004). The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: Expert panel review. Journal of Cancer Research and Clinical Oncology, 130, 1–7.PubMedCrossRef

Minotti, G., Recalcati, S., Menna, P., Salvatorelli, E., Corna, G., & Cairo, G. (2004). Doxorubicin cardiotoxicity and the control of iron metabolism: Quinone-dependent and independent mechanisms. Methods in Enzymology, 378, 340–361.PubMed

Herman, E. H., & Ferrans, V. J. (1990). Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Cancer Treatment Reviews, 17, 155–160.PubMedCrossRef

Hasinoff, B. B., Hellmann, K., Herman, E. H., & Ferrans, V. J. (1998). Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Current Medicinal Chemistry, 5, 1–28.PubMed

Diop, N. K., Vitellaro, L. K., Arnold, P., Shang, M., & Marusak, R. A. (2000). Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: Solid state structure, solution thermodynamics, and DNA cleavage activity. Journal of Inorganic Biochemistry, 78, 209–216.PubMedCrossRef

Hasinoff, B. B., Schroeder, P. E., & Patel, D. (2003). The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Molecular Pharmacology, 64, 670–678.PubMedCrossRef

Hasinoff, B. B. (2002). Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovascular Toxiciology, 2, 111–118.CrossRef

Fortune, J. M., & Osheroff, N. (2000). Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Progress in Nucleic Acid Research Molecular Biology, 64, 221–253.CrossRef

Swift, L. M., & Sarvazyan, N. (2000). Localization of dichlorofluorescin in cardiac myocytes: Implications for assessment of oxidative stress. American Journal of Physiology and Heart and Circulatory Physiology, 278, H982–H990.

10.

Hasinoff, B. B., Schnabl, K. L., Marusak, R. A., Patel, D., & Huebner, E. (2003). Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovascular Toxiciology, 3, 89–99.CrossRef

11.

Sarvazyan, N. (1996). Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. American Journal of Physiology, 271, H2079–H2085.PubMed

12.

Malisza, K. L., & Hasinoff, B. B. (1996). Hydroxyl radical production by the iron complex of the hydrolysis product of the antioxidant cardioprotective agent ICRF-187 (dexrazoxane). Redox Report, 2, 69–73.

13.

Schroeder, P. E., Jensen, P. B., Sehested, M., Hofland, K. F., Langer, S. W., & Hasinoff, B. B. (2003). Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemotherapy and Pharmacology, 52, 167–174.PubMedCrossRef

14.

Schroeder, P. E., & Hasinoff, B. B. (2005). Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal chelating form in the rat. Drug Metabolism and Disposition, 33, 1367–1372.PubMedCrossRef

15.

Hasinoff, B. B., Kuschak, T. I., Yalowich, J. C., & Creighton, A. M. (1995). A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochemical Pharmacology, 50, 953–958.PubMedCrossRef

16.

Classen, S., Olland, S., & Berger, J. M. (2003). Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proceedings of the National Academy Sciences of the United States of America, 100, 14510.CrossRef

17.

Hasinoff, B. B., Abram, M. E., Chee, G.-L., Huebner, E., Byard, E. H., Barnabé, N., Ferrans, V. J., Yu, Z.-X., & Yalowich, J. C. (2000). The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells. The Journal of Pharmacology and Experimental Therapeutics, 295, 474–483.PubMed

18.

Hasinoff, B. B., Abram, M. E., Barnabé, N., Khelifa, T., Allan, W. P., & Yalowich, J. C. (2001). The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Molecular Pharmacology, 59, 453–461.PubMed

19.

Hasinoff, B. B., Yalowich, J. C., Ling, Y., & Buss, J. L. (1996). The effect of dexrazoxane (ICRF-87) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs, 7, 558–567.PubMedCrossRef

20.

Sehested, M., Jensen, P. B., Sorensen, B. S., Holm, B., Friche, E., & Demant, E. J. F. (1993). Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochemical Pharmacology, 46, 389–393.PubMedCrossRef

21.

Hasinoff, B. B., Kuschak, T. I., Creighton, A. M., Fattman, C. L., Allan, W. P., Thampatty, P., & Yalowich, J. C. (1997). Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochemical Pharmacology, 53, 1843–1853.PubMedCrossRef

22.

Pouillart, P. (2004). Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. Cancer Treatment Reviews, 30, 643–650.PubMedCrossRef

23.

Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., Speyer, J., Mittelman, A., Reddy, S., Pendergrass, K., Velez-Garcia, E., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997). Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. Journal of Clinical Oncology, 15, 1318–1332.PubMed

Titel: Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
verfasst von: Brian B. Hasinoff
Eugene H. Herman
Publikationsdatum: 01.06.2007
Verlag: Humana Press Inc
Erschienen in: Cardiovascular Toxicology / Ausgabe 2/2007
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-007-0023-3

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Ongoing phase I and II studies of novel anthracyclines

An introduction to the metabolic determinants of anthracycline cardiotoxicity

Anthracycline cardiotoxicity in long-term survivors of childhood cancer

Role of mtDNA lesions in anthracycline cardiotoxicity

Novel antioxidants in anthracycline cardiotoxicity

Anthracycline-induced phospholipase A2 inhibition